The Experts below are selected from a list of 27921 Experts worldwide ranked by ideXlab platform
Xiaoyuan Chen - One of the best experts on this subject based on the ideXlab platform.
-
host guest chemistry in supramolecular Theranostics
Theranostics, 2019Co-Authors: Guocan Yu, Xiaoyuan ChenAbstract:Macrocyclic hosts, such as cyclodextrins, calixarenes, cucurbiturils, and pillararenes, exhibit unparalleled advantages in disease diagnosis and therapy over the past years by fully taking advantage of their host-guest molecular recognitions. The dynamic nature of the non-covalent interactions and selective host-guest complexation endow the resultant nanomaterials with intriguing properties, holding promising potentials in theranostic fields. Interestingly, the differences in microenvironment between the abnormal and normal cells/tissues can be employed as the stimuli to modulate the host-guest interactions, realizing the purpose of precise diagnosis and specific delivery of drugs to lesion sites. In this review, we summarize the progress of supramolecular Theranostics on the basis of host-guest chemistry benefiting from their fantastic topological structures and outstanding supramolecular chemistry. These state-of-the-art examples provide new methodologies to overcome the obstacles faced by the traditional theranostic systems, promoting their clinical translations.
-
breaking the depth dependence by nanotechnology enhanced x ray excited deep cancer Theranostics
Advanced Materials, 2019Co-Authors: Wei Tang, Zheyu Shen, Xiaoyuan ChenAbstract:: The advancements in nanotechnology have created multifunctional nanomaterials aimed at enhancing diagnostic accuracy and treatment efficacy for cancer. However, the ability to target deep-seated tumors remains one of the most critical challenges for certain nanomedicine applications. To this end, X-ray-excited theranostic techniques provide a means of overcoming the limits of light penetration and tissue attenuation. Herein, a comprehensive overview of the recent advances in nanotechnology-enhanced X-ray-excited imaging and therapeutic methodologies is presented, with an emphasis on the design of multifunctional nanomaterials for contrast-enhanced computed tomography (CT) imaging, X-ray-excited optical luminescence (XEOL) imaging, and X-ray-excited multimodal synchronous/synergistic therapy. The latter is based on the concurrent use of radiotherapy with chemotherapy, gas therapy, photodynamic therapy, or immunotherapy. Moreover, the featured biomedical applications of X-ray-excited deep Theranostics are discussed to highlight the advantages of X-ray in high-sensitivity detection and efficient elimination of malignant tumors. Finally, key issues and technical challenges associated with this deep theranostic technology are identified, with the intention of advancing its translation into the clinic.
-
cancer associated stimuli driven turn on Theranostics for multimodality imaging and therapy
Advanced Materials, 2017Co-Authors: Xingshu Li, Juyoung Yoon, Xiaoyuan ChenAbstract:Advances in bioinformatics, genomics, proteomics, and metabolomics have facilitated the development of novel anticancer agents that have decreased side effects and increased safety. Theranostics, systems that have combined therapeutic effects and diagnostic capabilities, have garnered increasing attention recently because of their potential use in personalized medicine, including cancer-targeting treatments for patients. One interesting approach to achieving this potential involves the development of cancer-associated, stimuli-driven, turn on Theranostics. Multicomponent constructs of this type would have the capability of selectively delivering therapeutic reagents into cancer cells or tumor tissues while simultaneously generating unique signals that can be readily monitored under both in vitro and in vivo conditions. Specifically, their combined anticancer activities and selective visual signal respond to cancer-associated stimuli, would make these theranostic agents more highly efficient and specific for cancer treatment and diagnosis. This article focuses on the progress of stimuli-responsive turn on Theranostics that activate diagnostic signals and release therapeutic reagents in response to the cancer-associated stimuli. The present article not only provides the fundamental backgrounds of diagnostic and therapeutic tools that have been widely utilized for developing theranostic agents, but also discusses the current approaches for developing stimuli-responsive turn on Theranostics.
-
revealing the self assembly pathways and nanomechanics of enzyme triggered nanofibers from peptide amphiphiles for cancer Theranostics
Biophysical Journal, 2016Co-Authors: Peng Huang, Hsienshun Liao, Ferenc Horkay, Xiaoyuan ChenAbstract:We have developed a tumor-specific phosphatase-triggered co-assembly strategy of indocyanine green (ICG)-doped nanofibers for cancer Theranostics (1). This strategy relies on targeted peptide self-assemblies to improve the critical tumor uptake of ICG and its photoacoustic and photothermal properties. We demonstrated complete tumor elimination by photo-thermal therapy with high therapeutic accuracy within 24-48 hours post-injection. We have conducted extensive AFM investigations in vitro to delineate the fundamental understanding of the phosphatase-instructed formation of nanofibers. This process is crucial to its theranostic capability, and can be generalized to the self-assembly pathways of other triggered peptide hydrogelators. Our AFM results reveal a coexistence of multiple conformational structures such as the nanosheets and nanofibers with distinct nanomechnical properties. Additionally, AFM results also reveal that water can induce conformational change from nanosheets to nanofibers, which shows the dominant hydrophobic interactions during the self-assembly process. Peptide hydrogels are widely used in various biological applications, such as drug delivery and tissue engineering owing to their fibrous structure that provides the advantages of high water content and biocompatibility. This work illustrates that AFM is a powerful biophysical tool in nanomedicine for probing the structure and mechanical properties of complex biopolymer systems. Ref(1) “Tumor-Specific Formation of Enzyme-Instructed Supramolecular Self-Assemblies as Cancer Theranostics.” Huang P, Gao Y, Lin J, Hu H, Liao HS, Yan X, Tang Y, Jin A, Song J, Niu G, Zhang G, Horkay F, Chen X. ACS Nano. 2015, DOI: 10.1021/acsnano.5b03874.
-
protein based photothermal Theranostics for imaging guided cancer therapy
Nanoscale, 2015Co-Authors: Peng Huang, Pengfei Rong, Lun Yu, Wenbin Zeng, Wei Wang, Xiaoyuan ChenAbstract:The development of imageable photothermal Theranostics has attracted considerable attention for imaging guided photothermal therapy (PTT) with high tumor ablation accuracy. In this study, we strategically constructed a near-infrared (NIR) cyanine dye by introducing a rigid cyclohexenyl ring to the heptamethine chain to obtain a heptamethine dye CySCOOH with high fluorescence intensity and good stability. By covalent conjugation of CySCOOH onto human serum albumin (HSA), the as-prepared HSA@CySCOOH nanoplatform is highly efficient for NIR fluorescence/photoacoustic/thermal multimodality imaging and photothermal tumor ablation. The theranostic capability of HSA@CySCOOH was systematically evaluated both in vitro and in vivo. Most intriguingly, complete tumor elimination was achieved by intravenous injection of HSA@CySCOOH (CySCOOH, 1 mg kg−1; 808 nm, 1.0 W cm−2 for 5 min) into 4T1 tumor-bearing mice, with no weight loss, noticeable toxicity, or tumor recurrence being observed. This as-prepared protein-based nanoTheranostics exhibits high water dispersibility, no off target cytotoxicity, and good biodegradability and biocompatibility, thus facilitating its clinical translation to cancer photothermal Theranostics.
Nicholas A. Peppas - One of the best experts on this subject based on the ideXlab platform.
-
responsive theranostic systems integration of diagnostic imaging agents and responsive controlled release drug delivery carriers
Accounts of Chemical Research, 2011Co-Authors: Mary Caldoreramoore, William B. Liechty, Nicholas A. PeppasAbstract:The ability to non-invasively monitor and treat physiological conditions within the human body has been an aspiration of researchers and medical professionals for decades. The emergences of nanotechnology opened up new possibilities for effective vehicles that could accomplish non-invasive detection of diseases and localized treatment systems to be developed. In turn, extensive research efforts have been spent on the development of imaging moiety that could be used to seek out specific diseased conditions and can be monitored with convention clinical imaging modalities. Nanoscale detection agents like these have the potential to increase early detection of pathophysiological conditions because they have the capability to detect abnormal cells before they even develop into diseased tissue and/or tumors. Once the diseased cells are detected it would be constructive to just be able to treat them simultaneously. From here, the concept of multifunctional carriers that could target, detect, and treat diseased cells emerged. The term “Theranostics” has been created to describe this promising area of research that focuses on the combination of diagnostic detection agents with therapeutic drug delivery carriers. Targeted theranostic nanocarriers offer an attractive improvement to disease treatment because of their ability to simultaneously diagnose, image, and treat at targeted diseased sites. Research efforts in the field of Theranostics encompass a broad variety of drug delivery vehicles, detection agents, and targeting modalities for the development of an all-in-one, localized, diagnostic and treatment system. Nanotheranostic systems that utilize metallic or magnetic imaging nanoparticles have the added capability to be used as thermal therapeutic systems. This review aims to explore recent advancements in the field of nanoTheranostics and the various fundamental components of an effective theranostic carrier.
-
Responsive theranostic systems: Integration of diagnostic imaging agents and responsive controlled release drug delivery carriers
Accounts of Chemical Research, 2011Co-Authors: Mary E. Caldorera-Moore, William B. Liechty, Nicholas A. PeppasAbstract:For decades, researchers and medical professionals have aspired to develop mechanisms for noninvasive treatment and monitoring of pathological conditions within the human body. The emergence of nanotechnology has spawned new opportunities for novel drug delivery vehicles capable of concomitant detection, monitoring, and localized treatment of specific disease sites. In turn, researchers have endeavored to develop an imaging moiety that could be functionalized to seek out specific diseased conditions and could be monitored with conventional clinical imaging modalities. Such nanoscale detection systems have the potential to increase early detection of pathophysiological conditions because they can detect abnormal cells before they even develop into diseased tissue or tumors. Ideally, once the diseased cells are detected, clinicians would like to treat those cells simultaneously. This idea led to the concept of multifunctional carriers that could target, detect, and treat diseased cells. The term "Theranostics" has been created to describe this promising area of research that focuses on the combination of diagnostic detection agents with therapeutic drug delivery carriers. Targeted theranostic nanocarriers offer an attractive improvement to disease treatment because of their ability to execute simultaneous functions at targeted diseased sites. Research efforts in the field of Theranostics encompass a broad variety of drug delivery vehicles, imaging contrast agents, and targeting modalities for the development of an all-in-one, localized detection and treatment system. Nanotheranostic systems that utilize metallic or magnetic imaging nanoparticles can also be used as thermal therapeutic systems. This Account explores recent advances in the field of nanoTheranostics and the various fundamental components of an effective theranostic carrier.
Peng Huang - One of the best experts on this subject based on the ideXlab platform.
-
2019 Applied Materials Today-Black P was stablized by Polydopamine coating for enhanced PTT
Applied Materials Today, 2019Co-Authors: Zhongjun Li, Jundong Shao, Jing Lin, Han Xu, Han Zhang, Jianqing Li, Feng Zhang, Peng HuangAbstract:Black phosphorus (BP) is a promising theranostic agent owing to its excellent photothermal property, biocompatibility and biodegradability. However, the rapid degradation of BP with oxygen and moisture causes the innate instability that is the Achilles’ heel of BP, hindering its further applications in cancer Theranostics. Herein, a facile surface passivation strategy was developed to prepare polydopamine (PDA) coated BP quantum dots (QDs) (denoted as BP@PDA) through self-polymerization method. PDA with enriched phenol groups plays as a scavenger of reactive oxygen, which can efficiently prevent the oxidation of BP quantum dots and make them much stable in water (∼90% for BP@PDA vs. only 10% for pure BP QDs after 10 days storage). Furthermore, PDA with strong near-infrared (NIR) absorption could greatly improve the photothermal conversion efficiency (PCE) of BP QDs from 22.6% to 64.2% (∼2.84-fold higher). Considering the excellent biodegradability and good biocompability of both BP QDs and PDA, the as-prepared BP@PDA hold great potential for cancer Theranostics.
-
revealing the self assembly pathways and nanomechanics of enzyme triggered nanofibers from peptide amphiphiles for cancer Theranostics
Biophysical Journal, 2016Co-Authors: Peng Huang, Hsienshun Liao, Ferenc Horkay, Xiaoyuan ChenAbstract:We have developed a tumor-specific phosphatase-triggered co-assembly strategy of indocyanine green (ICG)-doped nanofibers for cancer Theranostics (1). This strategy relies on targeted peptide self-assemblies to improve the critical tumor uptake of ICG and its photoacoustic and photothermal properties. We demonstrated complete tumor elimination by photo-thermal therapy with high therapeutic accuracy within 24-48 hours post-injection. We have conducted extensive AFM investigations in vitro to delineate the fundamental understanding of the phosphatase-instructed formation of nanofibers. This process is crucial to its theranostic capability, and can be generalized to the self-assembly pathways of other triggered peptide hydrogelators. Our AFM results reveal a coexistence of multiple conformational structures such as the nanosheets and nanofibers with distinct nanomechnical properties. Additionally, AFM results also reveal that water can induce conformational change from nanosheets to nanofibers, which shows the dominant hydrophobic interactions during the self-assembly process. Peptide hydrogels are widely used in various biological applications, such as drug delivery and tissue engineering owing to their fibrous structure that provides the advantages of high water content and biocompatibility. This work illustrates that AFM is a powerful biophysical tool in nanomedicine for probing the structure and mechanical properties of complex biopolymer systems. Ref(1) “Tumor-Specific Formation of Enzyme-Instructed Supramolecular Self-Assemblies as Cancer Theranostics.” Huang P, Gao Y, Lin J, Hu H, Liao HS, Yan X, Tang Y, Jin A, Song J, Niu G, Zhang G, Horkay F, Chen X. ACS Nano. 2015, DOI: 10.1021/acsnano.5b03874.
-
protein based photothermal Theranostics for imaging guided cancer therapy
Nanoscale, 2015Co-Authors: Peng Huang, Pengfei Rong, Lun Yu, Wenbin Zeng, Wei Wang, Xiaoyuan ChenAbstract:The development of imageable photothermal Theranostics has attracted considerable attention for imaging guided photothermal therapy (PTT) with high tumor ablation accuracy. In this study, we strategically constructed a near-infrared (NIR) cyanine dye by introducing a rigid cyclohexenyl ring to the heptamethine chain to obtain a heptamethine dye CySCOOH with high fluorescence intensity and good stability. By covalent conjugation of CySCOOH onto human serum albumin (HSA), the as-prepared HSA@CySCOOH nanoplatform is highly efficient for NIR fluorescence/photoacoustic/thermal multimodality imaging and photothermal tumor ablation. The theranostic capability of HSA@CySCOOH was systematically evaluated both in vitro and in vivo. Most intriguingly, complete tumor elimination was achieved by intravenous injection of HSA@CySCOOH (CySCOOH, 1 mg kg−1; 808 nm, 1.0 W cm−2 for 5 min) into 4T1 tumor-bearing mice, with no weight loss, noticeable toxicity, or tumor recurrence being observed. This as-prepared protein-based nanoTheranostics exhibits high water dispersibility, no off target cytotoxicity, and good biodegradability and biocompatibility, thus facilitating its clinical translation to cancer photothermal Theranostics.
-
tumor specific formation of enzyme instructed supramolecular self assemblies as cancer Theranostics
ACS Nano, 2015Co-Authors: Peng Huang, Hao Hu, Hsienshun Liao, Yuxia Tang, Jibin Song, Guofeng Zhang, Ferenc Horkay, Xiaoyuan ChenAbstract:Despite the effort of developing various nanodelivery systems, most of them suffer from undesired high uptakes by the reticuloendothelial system, such as liver and spleen. Herein we develop an endogenous phosphatase-triggered coassembly strategy to form tumor-specific indocyanine green (ICG)-doped nanofibers (5) for cancer Theranostics. Based on coordinated intermolecular interactions, 5 significantly altered near-infrared absorbance of ICG, which improves the critical photoacoustic and photothermal properties. The phosphatase-instructed coassembly process, as well as its theranostic capability, was successfully conducted at different levels ranging from in vitro, living cell, tissue mimic, to in vivo. Specifically, the tumor uptake of ICG was markedly increased to 15.05 ± 3.78%ID/g, which was 25-fold higher than that of free ICG (0.59 ± 0.24%ID/g) at 4 h after intravenous injection. The resulting ultrahigh T/N ratios (>15) clearly differentiated tumors from the surrounding normal tissue. Complete tumor e...
-
optical and photoacoustic dual modality imaging guided synergistic photodynamic photothermal therapies
Nanoscale, 2015Co-Authors: Hao Hu, Peng Huang, Shaoliang Zhang, Baozhong Shen, Xiaoyuan ChenAbstract:Phototherapies such as photodynamic therapy (PDT) and photothermal therapy (PTT), due to their specific spatiotemporal selectivity and minimal invasiveness, have been widely investigated as alternative treatments of malignant diseases. Graphene and its derivatives not only have been used as carriers to deliver photosensitizers for PDT, but also as photothermal conversion agents (PTCAs) for PTT. Herein, we strategically designed and produced a novel photo-theranostic platform based on sinoporphyrin sodium (DVDMS) photosensitizer-loaded PEGylated graphene oxide (GO-PEG-DVDMS) for enhanced fluorescence/photoacoustic (PA) dual-modal imaging and combined PDT and PTT. The GO-PEG carrier drastically improves the fluorescence of loaded DVDMS via intramolecular charge transfer. Concurrently, DVDMS significantly enhances the near-infrared (NIR) absorption of GO for improved PA imaging and PTT. The cancer theranostic capability of the as-prepared GO-PEG-DVDMS was carefully investigated both in vitro and in vivo. This novel Theranostics is well suited for fluorescence/PA dual-modal imaging and synergistic PDT/PTT.
William B. Liechty - One of the best experts on this subject based on the ideXlab platform.
-
responsive theranostic systems integration of diagnostic imaging agents and responsive controlled release drug delivery carriers
Accounts of Chemical Research, 2011Co-Authors: Mary Caldoreramoore, William B. Liechty, Nicholas A. PeppasAbstract:The ability to non-invasively monitor and treat physiological conditions within the human body has been an aspiration of researchers and medical professionals for decades. The emergences of nanotechnology opened up new possibilities for effective vehicles that could accomplish non-invasive detection of diseases and localized treatment systems to be developed. In turn, extensive research efforts have been spent on the development of imaging moiety that could be used to seek out specific diseased conditions and can be monitored with convention clinical imaging modalities. Nanoscale detection agents like these have the potential to increase early detection of pathophysiological conditions because they have the capability to detect abnormal cells before they even develop into diseased tissue and/or tumors. Once the diseased cells are detected it would be constructive to just be able to treat them simultaneously. From here, the concept of multifunctional carriers that could target, detect, and treat diseased cells emerged. The term “Theranostics” has been created to describe this promising area of research that focuses on the combination of diagnostic detection agents with therapeutic drug delivery carriers. Targeted theranostic nanocarriers offer an attractive improvement to disease treatment because of their ability to simultaneously diagnose, image, and treat at targeted diseased sites. Research efforts in the field of Theranostics encompass a broad variety of drug delivery vehicles, detection agents, and targeting modalities for the development of an all-in-one, localized, diagnostic and treatment system. Nanotheranostic systems that utilize metallic or magnetic imaging nanoparticles have the added capability to be used as thermal therapeutic systems. This review aims to explore recent advancements in the field of nanoTheranostics and the various fundamental components of an effective theranostic carrier.
-
Responsive theranostic systems: Integration of diagnostic imaging agents and responsive controlled release drug delivery carriers
Accounts of Chemical Research, 2011Co-Authors: Mary E. Caldorera-Moore, William B. Liechty, Nicholas A. PeppasAbstract:For decades, researchers and medical professionals have aspired to develop mechanisms for noninvasive treatment and monitoring of pathological conditions within the human body. The emergence of nanotechnology has spawned new opportunities for novel drug delivery vehicles capable of concomitant detection, monitoring, and localized treatment of specific disease sites. In turn, researchers have endeavored to develop an imaging moiety that could be functionalized to seek out specific diseased conditions and could be monitored with conventional clinical imaging modalities. Such nanoscale detection systems have the potential to increase early detection of pathophysiological conditions because they can detect abnormal cells before they even develop into diseased tissue or tumors. Ideally, once the diseased cells are detected, clinicians would like to treat those cells simultaneously. This idea led to the concept of multifunctional carriers that could target, detect, and treat diseased cells. The term "Theranostics" has been created to describe this promising area of research that focuses on the combination of diagnostic detection agents with therapeutic drug delivery carriers. Targeted theranostic nanocarriers offer an attractive improvement to disease treatment because of their ability to execute simultaneous functions at targeted diseased sites. Research efforts in the field of Theranostics encompass a broad variety of drug delivery vehicles, imaging contrast agents, and targeting modalities for the development of an all-in-one, localized detection and treatment system. Nanotheranostic systems that utilize metallic or magnetic imaging nanoparticles can also be used as thermal therapeutic systems. This Account explores recent advances in the field of nanoTheranostics and the various fundamental components of an effective theranostic carrier.
Mary E. Caldorera-Moore - One of the best experts on this subject based on the ideXlab platform.
-
Responsive theranostic systems: Integration of diagnostic imaging agents and responsive controlled release drug delivery carriers
Accounts of Chemical Research, 2011Co-Authors: Mary E. Caldorera-Moore, William B. Liechty, Nicholas A. PeppasAbstract:For decades, researchers and medical professionals have aspired to develop mechanisms for noninvasive treatment and monitoring of pathological conditions within the human body. The emergence of nanotechnology has spawned new opportunities for novel drug delivery vehicles capable of concomitant detection, monitoring, and localized treatment of specific disease sites. In turn, researchers have endeavored to develop an imaging moiety that could be functionalized to seek out specific diseased conditions and could be monitored with conventional clinical imaging modalities. Such nanoscale detection systems have the potential to increase early detection of pathophysiological conditions because they can detect abnormal cells before they even develop into diseased tissue or tumors. Ideally, once the diseased cells are detected, clinicians would like to treat those cells simultaneously. This idea led to the concept of multifunctional carriers that could target, detect, and treat diseased cells. The term "Theranostics" has been created to describe this promising area of research that focuses on the combination of diagnostic detection agents with therapeutic drug delivery carriers. Targeted theranostic nanocarriers offer an attractive improvement to disease treatment because of their ability to execute simultaneous functions at targeted diseased sites. Research efforts in the field of Theranostics encompass a broad variety of drug delivery vehicles, imaging contrast agents, and targeting modalities for the development of an all-in-one, localized detection and treatment system. Nanotheranostic systems that utilize metallic or magnetic imaging nanoparticles can also be used as thermal therapeutic systems. This Account explores recent advances in the field of nanoTheranostics and the various fundamental components of an effective theranostic carrier.
